Dana Stallings, NP
Family · Franklin, VANPI 1770021545
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,954 of the $224,736 with a category attached, or 76.1%. 33 manufacturers reported payments, led by Medtronic at 44.0% of the total. 2025 is the largest year on record at $72,721, 6.9 times the $10,599 reported in 2021. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 732 payments — averaging $307.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$99K
- Lilly USA, LLC$98K
- Novo Nordisk$24K
- Insulet Corporation$453
- Corcept Therapeutics$411
- AstraZeneca$328
- plus $2K from 27 others
What the payments were for
- Consulting fees$11,8405%
- Speaking & faculty fees$170,95476%
- Travel & lodging$28,02212%
- Food & beverage$13,8726%
- Education$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 286 | $98,950 |
| Lilly USA, LLC | 263 | $97,961 |
| Novo Nordisk | 52 | $24,496 |
| Insulet Corporation | 11 | $453 |
| Corcept Therapeutics | 9 | $411 |
| AstraZeneca | 14 | $328 |
| Amgen | 12 | $279 |
| Bayer | 20 | $241 |
| Johnson & Johnson | 6 | $232 |
| Tempus AI, Inc | 3 | $198 |
| Boehringer Ingelheim | 11 | $181 |
| GSK | 9 | $179 |
| Globus Medical | 1 | $120 |
| Sanofi-aventis U.S. LLC | 6 | $117 |
| Merck | 4 | $64 |
| Neurocrine Biosciences, Inc. | 2 | $64 |
| Advanced Respiratory, Inc | 2 | $41 |
| Novartis | 2 | $38 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Zealand Pharma US, Inc. | 1 | $33 |
| Cequr Corporation | 1 | $33 |
| Xeris Pharmaceuticals, Inc. | 2 | $31 |
| Sequel Med Tech, LLC | 1 | $31 |
| Dexcom, Inc. | 2 | $30 |
| Pfizer | 1 | $25 |
| Abbott | 1 | $25 |
| Mannkind Corporation | 1 | $24 |
| Electromed, Inc. | 2 | $23 |
| BETA Bionics, Inc. | 1 | $21 |
| Tandem Diabetes Care, Inc. | 1 | $19 |
| Alkermes, Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$94,147
- MINIMED 780G$53,521
- MINIMED 770G$14,430
- RYBELSUS$11,900
- Ozempic$9,523
- InPen$5,100
- INPEN SMART INSULIN DELIVERY SYSTEM$4,078
- Minimed 770G System$2,992
- Korlym$273
- SPRAVATO$133
- Senza$120
- Omnipod$111
- Repatha$106
- FARXIGA$102
- Tempus Pixel$100
How this compares
$224,736 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 426 | $754,601 |
| MounjaroTirzepatide | 307 | $564,284 |
| TrulicityDulaglutide | 169 | $280,370 |
| JardianceEmpagliflozin | 139 | $159,546 |
| KerendiaFinerenone | 123 | $132,449 |
| Humalog Kwikpen U-200Insulin Lispro | 20 | $103,200 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 57 | $81,343 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 80 | $80,181 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $71,408 |
| HumalogInsulin Lispro | 147 | $66,742 |
| FarxigaDapagliflozin Propanediol | 45 | $62,194 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 35 | $59,730 |
| Repatha SureclickEvolocumab | 32 | $40,595 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $36,778 |
| NovologInsulin Aspart | 61 | $29,529 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $97,961 | $930,919741 claims |
| Novo NordiskOzempic, Novolog, Fiasp | $24,496 | $808,257506 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $181 | $219,276174 claims |
| BayerKerendia | $241 | $132,449123 claims |
| AstraZenecaFarxiga | $328 | $62,19445 claims |
| MerckJanuvia, Janumet Xr | $64 | $25,98439 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $117 | $21,70912 claims |
| Johnson & JohnsonInvokana | $232 | $7,06412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Franklin
- Lauren HeckenlaibleFranklin$26K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
- Casey SharpDanville$63K
- Norman JacobowitzManassas$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.